TYK2/JAK1 inhibitor, in severe phase COVID-19.27 Oct 2020 16:16
SDC-1801 is designed to inhibit the occurrence of a ‘cytokine storm’, an overreaction of the immune system that leads to acute respiratory distress syndrome and can cause illnesses such as coronavirus, SARS, MERS and influenza to be fatal.
"We are delighted that UKRI has indicated its conditional support for our programme to investigate the therapeutic potential of SDC-1801, our proprietary TYK2/JAK1 inhibitor, in severe phase [coronavirus]”, Sareum’s chief scientific officer John Reader said in a statement.
“There is a pressing need for new therapies to treat this potentially life-threatening disease, and there is evidence to show that TYK2/JAK1 signalling may play an important role in the inflammatory cascade that leads to the cytokine storm observed in some patients", he added.
“There is a pressing need indeed, before it kills half the world population..
308..